Kardigan Reports Q2 2026 Results: $660.7M Cash, Three Phase 2/3 Trials Advancing
KARD is trading near its 52-week low of $19.58 (4.2% above the low).
Summary
Kardigan reported Q2 2026 results with $660.7 million in cash, a $116.2 million net loss, and clinical updates showing all three lead programs advancing toward data readouts in the first half of 2027.
Key Events · Earnings and Guidance · KARD
-
Strong Cash Position
Cash, cash equivalents and investments totaled $660.7 million as of June 30, 2026, up from $335.5 million at year-end 2025, reflecting net IPO proceeds. Management expects this runway to fund operations through multiple data readouts and Phase 3 trial initiations.
-
Widened Net Loss
Net loss was $116.2 million for Q2 2026, compared to $57.4 million in Q2 2025, primarily due to a $43.5 million non-cash change in fair value of contingent milestone liabilities and increased R&D expenses ($56.4 million vs. $35.8 million).
-
Three Programs Advancing
Danicamtiv (genetic DCM): Phase 3 KINSHIP-DCM enrollment underway, Phase 2b data expected 1H 2027. Ataciguat (CAVS): Phase 2b KATALYST-AV data expected 1H 2027. Tonlamarsen (ASH): Phase 2 KARDINAL-ASH first patient dosed, data expected 1H 2027.
-
Upcoming Data Presentations
Preclinical/clinical data on danicamtiv's right ventricular function effects and extended follow-up data on tonlamarsen in uncontrolled hypertension will be presented at ESC 2026 on August 30.
Analysis · KARD · Life Sciences
In its first quarterly report as a public company, Kardigan disclosed a robust cash position of $660.7 million following its upsized IPO, providing runway through multiple data readouts expected in the first half of 2027. The net loss widened to $116.2 million, driven by a $43.5 million non-cash charge for contingent milestone liabilities and higher R&D spending as three late-stage programs advance. With Phase 3 enrollment underway for danicamtiv and Phase 2 data for all three candidates expected within the next 12 months, the company is entering a catalyst-rich period that will define its registrational path.
At the time of this filing, KARD was trading at $20.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $19.58 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.